This study is in progress, not accepting new patients
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
Summary
- Eligibility
- for people ages 18-80 (full criteria)
- Location
- at San Diego, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Novartis Pharmaceuticals
- ID
- NCT04023552
- Phase
- Phase 3 Cardiovascular Disease Research Study
- Study Type
- Interventional
- Participants
- About 8323 people participating
- Last Updated